Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods

被引:40
作者
Euscher, Elizabeth [1 ]
Sui, Dawen [2 ]
Soliman, Pamela [3 ]
Westin, Shannon [3 ]
Ramalingam, Preetha [1 ]
Bassett, Roland [2 ]
Malpica, Anais [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
关键词
Endometrial cancer; Sentinel lymph node; Metastasis; Ultrastaging; CANCER; METASTASIS; BIOPSY; RISK; INJECTION; ACCURACY; PATTERNS;
D O I
10.1097/PGP.0000000000000415
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Sentinel lymph node (SLN) sampling may provide staging information without exposing patients to risks of lymph node dissection. There is no consensus protocol for optimal pathologic handling of these specimens. This study compares 2 ultrastaging protocols of SLN in endometrial carcinoma (EC). All SLN were serially sectioned perpendicular to the long axis in 2 mm intervals and entirely submitted for routine hematoxylin and eosin (H&E) processing. SLN negative by routine processing had ultrastaging (US) by one of the following: method 1 (M1), 5 H&E levels at 250 m intervals with 2 unstained slides at each level; pankeratin immunohistochemistry (IHC) performed on level 1 in cases with negative H&E levels or method 2 (M2), 1 H&E level + 2 unstained slides cut 250 m into the tissue block; pankeratin IHC performed in cases with negative H&E. Histologic subtype, numbers of SLN, positive SLN, non-SLN, positive non-SLN, and metastasis size were recorded. A total of 178 patients had 527 SLNs (1-16 per case; median, 2 SLN) sampled during hysterectomy for the following EC histotypes: endometrioid International Federation of Gynecology and Obstetrics grade 1/2, 117 (66%); endometrioid International Federation of Gynecology and Obstetrics grade 3, 18 (10%); serous, 20 (11%); carcinosarcoma, 11 (6%); clear cell, 9 (5%); and undifferentiated, 3 (2%). In all, 172 patients had ultrastaging: M1=65; M2=58. In total, 33 patients were SLN positive. Twenty-seven had SLN submitted for US: M1=11; M2=16. Eleven patients had additional SLN detected by US: M1=5; M2=6. Of these, 8 were patients whose SLN were only detected by US representing an increase of 32% in number of patients with positive SLN. Six patients (M1=2; M2=4) with negative SLN had a positive non-SLN. Mean size of ultrastage-detected metastasis was 0.24 mm for M1 and 0.38 mm for M2. Statistical analysis comparing M1 and M2 detected no statistically significant associations with respect to number of positive SLN detected, size of metastasis or false-negative rate and method. The methods performed similarly for both low-grade and high-grade EC. A more comprehensive US protocol had no significant advantages over a single wide interval and IHC in this study population. A pankeratin IHC stain enhances metastasis detection. Additional studies are required to further test this limited protocol as well as to evaluate the clinical significance of the low volume disease detected by ultrastaging.
引用
收藏
页码:242 / 251
页数:10
相关论文
共 50 条
  • [21] Sentinel Lymph Nodes in Endometrial Cancer Update 2018
    Abdelazim, Ibrahim A.
    Abu-Faza, Mohannad
    Zhurabekova, Gulmira
    Shikanova, Svetlana
    Karimova, Bakyt
    Sarsembayev, Mukhit
    Starchenko, Tatyana
    Mukhambetalyeva, Gulmira
    GYNECOLOGY AND MINIMALLY INVASIVE THERAPY-GMIT, 2019, 8 (03): : 94 - 100
  • [22] The Role of Sentinel Lymph Nodes in Endometrial and Cervical Cancer
    Smith, Blair
    Backes, Floor
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (07) : 753 - 760
  • [23] Unexpected locations of sentinel lymph nodes in endometrial cancer
    How, Jeffrey
    Boldeanu, Irina
    Lau, Susie
    Salvador, Shannon
    How, Emily
    Gotlieb, Raphael
    Abitbol, Jeremie
    Halder, Ajay
    Amajoud, Zainab
    Probst, Stephan
    Brin, Sonya
    Gotlieb, Walter
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 18 - 23
  • [24] Characteristics of Breast Carcinoma Cases With False-Negative Sentinel Lymph Nodes
    Wei, Shi
    Bleiweiss, Ira J.
    Nagi, Chandandeep
    Jaffer, Shabnam
    CLINICAL BREAST CANCER, 2014, 14 (04) : 280 - 284
  • [25] Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739)
    Backes, Floor J.
    Cohen, David
    Salani, Ritu
    Cohn, David E.
    O'Malley, David M.
    Fanning, Emily
    Suarez, Adrian A.
    Fowler, Jeffrey M.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 496 - 499
  • [26] The detection of sentinel lymph nodes in laparoscopic surgery can eliminate systemic lymphadenectomy for patients with early stage endometrial cancer
    Tanaka, Tomohito
    Terai, Yoshito
    Fujiwara, Satoe
    Tanaka, Yoshimichi
    Sasaki, Hiroshi
    Tsunetoh, Satoshi
    Yamamoto, Kazuhiro
    Yamada, Takashi
    Ohmichi, Masahide
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (02) : 305 - 313
  • [27] Evaluation of sentinel lymph nodes in vulvar, endometrial and cervical cancers
    Jenna Emerson
    Katina Robison
    World Journal of Obstetrics and Gynecology, 2016, (01) : 78 - 86
  • [28] An Extraordinary Location of Sentinel Lymph Nodes in a Patient with Endometrial Cancer
    Comba, Cihan
    Aslan, Erkan
    Vatankulu, Betul
    Tatar, Zeynep
    Demir, Ali Aslan
    Demir, Omer
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2023, 30 (08) : 613 - 614
  • [29] Sentinel lymph nodes in endometrial cancer: is hysteroscopic injection valid?
    Clement, D.
    Bats, A. S.
    Ghazzar-Pierquet, N.
    Belda, M. A. Le Frere
    Larousserie, F.
    Nos, C.
    Lecuru, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2008, 29 (03) : 239 - 241
  • [30] Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging
    Balaya, V
    Guani, B.
    Benoit, L.
    Magaud, L.
    Bonsang-Kitzis, H.
    Ngo, C.
    Le Frere-Belda, M. A.
    Mathevet, P.
    Lecuru, F.
    GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 576 - 583